Imclone LLC

Immunogen, Inc.

Paul J Balderes

Gregory D Plowman

Dale Lincoln Ludwig

Xiaoqiang Kang

Hans K Erickson

Christopher M Moxham

Alan C Rigby

Scott W Eastman

The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.

Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment

The present invention provides for fully human antibodies and chimeric antibodies that bind human TYRP1 antigen with an affinity comparable to or higher than TA99, a murine antibody specific to TYRP1. The invention further provides polynucleic acids and host cells that encode and express these antibodies. The invention also provides for methods of modulating activity of TYRP1, treating growth of a cancer cell, and treating a malignant melanoma in mammals by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment.

Anti-TYRP1 antibodies

Growing community of inventors

New York, NY, United States of America

Paul J Balderes